CKET NO. 2875.1001-007

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

In re Application of.

C. Thomas Caskey, John M. Shumaker and Andres Metspalu

Application No:

09/711,476

Filed:

For:

November 13, 2000

TECH CENTER 1600/2900

PARALLEL PRIMER EXTENSION APPROACH TO NUCLEIC ACID SEQUENCE ANALYSIS

The owners, Baylor College of Medicine (Houston, TX) and Pharmacia Biotech AB (SE) of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,153,379 The owners hereby agree that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantees, their successors or assigns.

In making the above disclaimer, the owners do not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The terminal disclaimer fee under 37 CFR 1 20(d) is enclosed.

The undersigned are empowered to act on behalf of the owners.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

	28 March 2002
Date	A T Pale
Signature	Signature Dr A J Rollins
Typed or printed name	Typed or printed name
Baylor College of Medicine	Pharmacia Biotech AB

04/19/2002 RMEBRART 00000023 09711476

00 70:146

110,00 OP

STATEMENT UNDER 37 C.F.R. § 3.73(b)

Applicar		C. Thomas Caskey, John M. S.	humaker and Andres Metspalu	哥	
zbbwen z	Nio	00/711 476	Filed: November 13, 2000	픙	A
For:		PARALLEL PRIMER EXTE	NSION APPROACH TO NUCLEIC ACID SEQUENCE ANALYSIS	TECH CENTER	APR 1
	Pharma	CIS BIOLOCH AR (Name of Assignee)	an <u>corporation</u> (Type of Assignce, e.g., corporation, partnership, university, government agr		9 2002
states th	at 11 15			8	
A	[]	the assignee of the entire righ	t, title and interest in the patent application identified above; or		
В.	[x]	application identified above.	of the cutive right, table and interest in the pater A separate Statement under 37 CFR § 3.73(b) is being submitted.		
The mg	ht, title a	ad interest of the above-named	assignee in the patent application identified above is established by virt	ne of:	
A. [X]		from the inventors of t	he patent application identified above. The assignment was recorded in frames 0809-0812, or a copy thereof is attached.	the Par	en t
OR					
B []	A chai	o of title from the inventor(s) o	f the patent application identified above, to the current assignee as show	n belov	N :
·	1.	From:	n the Patent and Trademark Office at or a copy thereof is attached.		
	2	From:	To: In the Patent and Trademark Office at, or a copy thereof is attached.		
	3.	From	To: I in the Patent and Trademark Office at or a copy thereof is aπached		
	[]	additional documents in the cha	ain of title are listed on a supplemental sheet.		
The u	ndersign	ed (whose title is supplied belo	w) is authorized to act on behalf of the assignee.		
Date:		28 March 2002			
Name	·	Dr A J Rollins			
Title	·	Vice President Grou	p Intellectual Property		
Sıgnı	пите	A:). Kolling			